FDA
-
-
-
-
-
-
-
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
-
-
-
-
-
-
-
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
-
-
-
-
-
-
-
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
-
-
-
-
-
-
-
Revvity partners with Sanofi to develop type 1 diabetes screening test
-
-
-
-
-
-
-
Sanofi to acquire Blueprint Medicines, $129 per share
-
-
-
-
-
-
-
Sanofi Q1 earnings preview: analysts focus on pipeline, US policy risks
-
-
-
-
-
-
-
US FDA approves Sanofi's bleeding disorder therapy
-
334,857 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


